DxN VERIS Molecular Diagnostics System - Cost and Time Effective
Beckman Coulter Diagnostics's DxN VERIS Molecular Diagnostics System* was recently showed at the 25th European Congress of Clinical Microbiology and Infectious Diseases, in Copenhagen, Denmark. The CE-marked system is now available with CE-marked assays for Human Cytomegalovirus (CMV) and Hepatitis B Virus (HBV)*. Additional assays for Human Immunodeficiency Virus (HIV-1) and Hepatitis C Virus (HCV) have been submitted for CE-mark certification*. Further menu expansion will follow with many other assays currently in development.
“The DxN VERIS Molecular Diagnostics System is designed to revolutionise the clinical laboratory with LEAN workflow and improved sample turn-around time,” said Arnd Kaldowski, president, Beckman Coulter Diagnostics. “The system’s true single sample random access empowers laboratories to perform viral load tests whenever they want, at a time that suits them—ultimately helping physicians make faster clinical decisions and positively impacting patients.”
The DxN VERIS Molecular Diagnostics System assays are supplied in a unique, single cartridge system that are cost- and time-effective. Unlike traditional batch-plate systems, there are no empty wells, so the DxN VERIS Molecular Diagnostics System reduces wastage and consumable costs. With the DxN VERIS Molecular Diagnostics System, all necessary consumables and reagents are on-board, so there is no lengthy set-up and tests can be up and running in less than 10 minutes.
“With rapid processing, the DxN VERIS Molecular Diagnostics System’s short run-times ensure that results are delivered to physicians as quickly as possible,” Richard Creager, senior vice president, Molecular Diagnostics Business Unit, and chief scientific officer at Beckman Coulter Diagnostics. “By consolidating DNA extraction, amplification and detection within a single instrument, we have significantly reduced manual intervention and are enabling labs to go from a sample to an answer in just 70 minutes.”
*Not for sale or distribution in the U.S.; not available in all markets.
Tags: Cytomegalovirus, Hepatitis C, HIV, Hepatitis B
Date Published: May 5, 2015
Source article link: Beckman Coulter Inc. » company contact details
Automated Hepatitis Viral Load Testing Offered at LabCorp
Vela Achieves CE-IVD Marking for HCV Genotyping NGS Assay
More CMV Positives Found with DxN VERIS vs COBAS®
Excellent Results from Multi-Centre Evaluation of DxN VERIS HIV-1 Assay